Neurocrine Biosciences (NASDAQ:NBIX) Releases Earnings Results, Misses Estimates By $0.48 EPS

Neurocrine Biosciences (NASDAQ:NBIX) posted its quarterly earnings results on Wednesday. The company reported $1.88 EPS for the quarter, missing analysts’ consensus estimates of $2.36 by ($0.48), FiscalAI reports. Neurocrine Biosciences had a net margin of 15.95% and a return on equity of 15.82%. The company had revenue of $805.50 million during the quarter, compared to analyst estimates of $804.21 million. During the same period last year, the firm earned $1.69 EPS. The firm’s revenue for the quarter was up 28.3% compared to the same quarter last year.

Here are the key takeaways from Neurocrine Biosciences’ conference call:

• INGREZZA posted a record year with double‑digit volume growth and management guided 2026 sales of $2.7–$2.8 billion, driven by expanded access and a larger salesforce.
• CRENESSITY exceeded expectations in its first full year with over $300 million in net sales and prescriptions covering roughly 10% of the classic CAH population, supporting the company’s view it can become a second blockbuster.
• The pipeline is progressing rapidly — two Phase 3 neuropsychiatry programs (osavampator in MDD and direlotide in schizophrenia) target top‑line data in 2027 and NBI‑890 has entered Phase 2 for tardive dyskinesia, setting up a data‑rich 2027.
• Financials are strong with total product sales above $2.8 billion (22% YoY), cash increasing to $2.5 billion, and roughly 30% non‑GAAP operating margin, enabling continued SG&A and R&D investments.
• Management acknowledged pricing concessions and formulary access investments reduced net pricing in 2025 and noted potential contracting/competitive pressure (deutetrabenazine MFP negotiations in 2027) that could weigh on future pricing and margins.

Neurocrine Biosciences Price Performance

Shares of NASDAQ:NBIX opened at $137.44 on Thursday. Neurocrine Biosciences has a one year low of $84.23 and a one year high of $160.18. The company has a market cap of $13.70 billion, a price-to-earnings ratio of 32.88, a PEG ratio of 0.65 and a beta of 0.31. The firm has a 50 day simple moving average of $141.39 and a 200 day simple moving average of $140.58.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong sales momentum — Net product sales were $798.3M in Q4 and $2.83B for full-year 2025, +29% and +22% year-over-year, respectively; company gave INGREZZA® full‑year 2026 net product sales guidance of $2.7–$2.8B, supporting revenue durability. Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
• Positive Sentiment: Analyst backing remains solid — Multiple recent buy/overweight ratings and a median analyst target ~ $179 indicate continued bullish consensus that could support the stock over time. Neurocrine Biosciences Inc. (NBIX) Stock Falls on Q4 2025 Earnings
• Neutral Sentiment: Revenue roughly in line with Street — Reported revenue ~$805.5M (~+28% YoY) compared closely to consensus estimates (mid-$800M), so top-line performance was not the primary driver of the move. Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
• Neutral Sentiment: Full disclosure and management color available — Earnings call transcript and slide deck were posted for investors to review guidance detail and pipeline commentary. Neurocrine Biosciences, Inc. (NBIX) Q4 2025 Earnings Call Transcript Slide Deck
• Negative Sentiment: EPS missed consensus — Reported EPS ($1.88) came in below several Street estimates (reports cite $2.25–$2.36 consensus), which is the main near-term catalyst pressuring the stock. Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
• Negative Sentiment: Market and insider signals — Several reports note an immediate post-earnings share drop and sizable insider sales disclosed in recent months, both of which can add short-term selling pressure. Neurocrine Biosciences Inc. (NBIX) Stock Falls on Q4 2025 Earnings
• Negative Sentiment: Cautious tone for 2026 highlighted by some outlets — Coverage describes company guidance as cautious despite strong Ingrezza sales, which may keep near-term sentiment muted until more clarity emerges. Neurocrine Biosciences beats Q4 expectations, offers cautious 2026 guidance

Wall Street Analysts Forecast Growth

Several equities analysts have commented on NBIX shares. Mizuho raised their target price on shares of Neurocrine Biosciences from $146.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, December 12th. TD Cowen lifted their price objective on shares of Neurocrine Biosciences from $175.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, December 5th. UBS Group lowered their price objective on shares of Neurocrine Biosciences from $188.00 to $178.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Canaccord Genuity Group upped their target price on Neurocrine Biosciences from $160.00 to $164.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Finally, HC Wainwright raised their target price on Neurocrine Biosciences from $168.00 to $198.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Fifteen analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $176.00.

Insider Activity at Neurocrine Biosciences

In other news, insider Darin Lippoldt sold 4,376 shares of the stock in a transaction on Monday, December 8th. The stock was sold at an average price of $159.65, for a total value of $698,628.40. Following the completion of the transaction, the insider directly owned 43,405 shares in the company, valued at approximately $6,929,608.25. This represents a 9.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leslie V. Norwalk sold 5,000 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $152.23, for a total value of $761,150.00. Following the sale, the director directly owned 7,429 shares in the company, valued at approximately $1,130,916.67. This trade represents a 40.23% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 61,966 shares of company stock valued at $8,625,166 over the last three months. 4.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in NBIX. AQR Capital Management LLC boosted its position in Neurocrine Biosciences by 83.7% during the 3rd quarter. AQR Capital Management LLC now owns 2,773,648 shares of the company’s stock worth $388,435,000 after buying an additional 1,263,633 shares during the period. Deerfield Management Company L.P. lifted its holdings in shares of Neurocrine Biosciences by 1.4% during the third quarter. Deerfield Management Company L.P. now owns 1,184,345 shares of the company’s stock worth $166,258,000 after purchasing an additional 16,543 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Neurocrine Biosciences by 3.8% in the third quarter. Dimensional Fund Advisors LP now owns 710,122 shares of the company’s stock worth $99,686,000 after purchasing an additional 25,683 shares during the last quarter. Armistice Capital LLC grew its stake in shares of Neurocrine Biosciences by 3.1% in the third quarter. Armistice Capital LLC now owns 697,022 shares of the company’s stock worth $97,848,000 after purchasing an additional 20,998 shares during the last quarter. Finally, Bank of America Corp DE increased its holdings in Neurocrine Biosciences by 16.4% in the second quarter. Bank of America Corp DE now owns 653,011 shares of the company’s stock valued at $82,077,000 after purchasing an additional 91,942 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.